Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]

Détails

ID Serval
serval:BIB_5A4B24BBA8FE
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]
Périodique
Revue medicale suisse
Auteur(s)
Moura B., Homicsko K., Berthod G., Cerottini J.P., Guggisberg D., Gaide O., Maillard M.H., Michielin O.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
20/05/2015
Volume
11
Numéro
475
Pages
1108,1110-1114
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
In recent years the therapy of metastatic melanoma has been revolutionized from a disease with very few efficient treatment options to one with access to multiple therapies which can impact on patient survival. Two main classes of therapies have been developed: 1. Immunotherapy by immune checkpoint inhibitors and 2. Small molecule inhibitors of the MAPK pathway. Immunotherapies achieved by either inhibition of CTLA-4 or the PD1/PD-Ll axes are impacting the overall survival in an important fraction of patients. In addition, the side effects of these immune therapy approaches require early detection by all the specialists involved as well as early management according to precise guidelines for optimal outcome.

Mots-clé
Drug-Related Side Effects and Adverse Reactions/therapy, Humans, Immunotherapy/adverse effects, Immunotherapy/methods, Immunotherapy/trends, Melanoma/immunology, Melanoma/therapy, Signal Transduction/immunology, Skin Neoplasms/immunology, Skin Neoplasms/therapy, Therapies, Investigational/adverse effects, Treatment Outcome, Vaccines/adverse effects
Pubmed
Création de la notice
02/11/2017 12:02
Dernière modification de la notice
20/08/2019 14:13
Données d'usage